micro-community-banner
Profile Image
  • Add Media
  • Saved

3yr
Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction - PubMed

Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35642772/

Heart failure with mildly reduced ejection fraction (HFmrEF) is associated with comparable poor outcomes as other subtypes of heart failure and remains a medical unmet need due to the paucity...



Conclusion/Relevance: Current limited evidence suggests that SGLT2is might be a favourable treatment modality for patients with HFmrEF to reduce hospitalization for heart failure and CV mortality. This conclusion needs to be further supported by clear HFmrEF subgroup analysis of the existing trials. Further outcome trials involving sufficient...

Profile Image
  • Saved

3yr
SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance - PubMed

SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35652305/

1 Department of Woman and Child's Health, University of Padova, Padova, Veneto, Italy. 2 Department of Pediatrics, Yale University, New Haven, Connecticut. 3 Department of Medicine, University of Maryland School...



Relevance: Insulin-resistant diabetes in Rabson-Mendenhall syndrome (RMS) is relatively unresponsive to first-line antidiabetic treatments, including metformin and insulin. We report 2 patients with RMS treated with 2 different sodium-glucose cotransporter inhibitors 2: empagliflozin in an 11-year-old boy and dapagliflozin in a 12-year-old...

Profile Image
  • Saved

3yr
Masked Primary Hyperparathyroidism by Empagliflozin Use

Masked Primary Hyperparathyroidism by Empagliflozin Use

Source : https://www.cureus.com/articles/76945-masked-primary-hyperparathyroidism-by-empagliflozin-use

Sodium-glucose cotransporter-2 inhibitors are drugs that regulate blood sugar by decreasing glucose reabsorption from the proximal renal tubules. Primary hyperparathyroidism masked by empagliflozin is very rare and only a few...



Relevance: Sodium-glucose cotransporter-2 inhibitors are drugs that regulate blood sugar by decreasing glucose reabsorption from the proximal renal tubules. Primary hyperparathyroidism masked by empagliflozin is very rare and only a few cases are reported in the literature. We report a case of a 57-year-old man with a known history of diabetes...

Profile Image
  • Saved

3yr
Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure

Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure

Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.859253/full

Clinical trials showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs developed for treating diabetes mellitus, improve prognosis of patients with heart failure (HF). However, the mechanisms for...



Conclusion: Our results indicate that EMPA has direct effects on the heart, independently of reductions in blood glucose, to enhance mitochondrial function by upregulating mitochondrial biogenesis, enhancing OXPHOS, reducing ROS production, attenuating apoptosis, and increasing autophagy to improve overall cardiac function in a non-diabetic...

Profile Image
  • Saved

3yr
Clinical trials show additional benefits of SGLT2 inhibitors

Results from randomized controlled trials have indicated that sodium glucose cotransporter 2 (SGLT2) inhibitors lower the chances of major adverse cardiovascular events (MACE). In the trials, MACE was defined as a composite of mortality due to cardiovascular causes, non-fatal MI, or non-fatal stroke. SGLT2 inhibitors also decreased the risk of all-cause mortality and heart failure compared with dipeptidyl peptidase-4 (DPP-4) inhibitors.

These studies have led to the use of select SGLT2 inhibitors as a means to treat heart failure regardless of type 2-diabetes or ejection-fraction status. SGLT2 inhibitors can be used in patients with heart failure with reduced or preserved ejection fraction (i.e., HFrEF, HFpEF). Mechanistically, these agents inhibit the reabsorption of filtered glucose, thus decreasing the risk of future heart-failure decompensation. 

What has been your clinical experience with SGLT2 inhibitors in heart failure patients? How does this class compare with other HF agents? Which HF patients are particularly responsive to SGLT2 inhibitors in your experience?

Profile Image
  • 3yr
    Thanks, All, for your wonderful responses! How do you compare SGLT2 inhibitors to other treatments for HF? How do you advise your patients on these drugs? Do your patients encounter Show More
  • 3yr
    SGLT2 inhibitor is gaining a huge momentum of my practice , I usually bring patients to office , to discuss the indication , start them on a sample , while Show More

Show More Comments